慢凝固经巩膜睫状体光凝在药物控制不佳的人工晶状体眼青光眼中的治疗结果
这项单中心回顾性病例系列纳入74例无既往青光眼手术史的人工晶状体眼青光眼患者,接受慢凝固连续波经巩膜睫状体光凝(1250 mW、4秒)。术后眼压从27.5±9.8 mmHg降至16.1±6.3 mmHg(P<.001),1年和2年累积成功率分别为60.6%和58.5%,基线眼压>21 mmHg者2年成功率为64.9%。
要点
- 慢凝固TSCPC作为人工晶状体眼青光眼初始手术可有效降低眼压并减少用药。
- 1年和2年累积成功率分别为60.6%和58.5%。
- 基线眼压>21 mmHg者2年成功率64.9%,≤21 mmHg者为45.5%(P=.144)。
核心结论
- 慢凝固TSCPC作为人工晶状体眼青光眼患者的初始手术干预具有良好疗效和安全性,尤其在基线眼压>21 mmHg的患者中。
研究设计与样本
- 单中心回顾性病例系列,纳入74例无既往青光眼手术史的人工晶状体眼青光眼患者,平均年龄82.6±12.5岁,平均随访18.7±9.1个月。
主要发现
- 眼压从术前27.5±9.8 mmHg降至术后16.1±6.3 mmHg(P<.001)。
- 青光眼用药数量从术前4.1±0.9降至术后3.1±1.3(P<.001)。
- 1年和2年累积成功率分别为60.6%和58.5%。
- 基线眼压>21 mmHg组与≤21 mmHg组的2年成功率分别为64.9%和45.5%(P=.144)。
- logMAR视力从0.70±0.64变为末次随访1.04±0.87(P=.01),未观察到严重并发症,多数并发症轻微且短暂。
关键数值与推荐
- 手术成功定义为眼压6-21 mmHg且较基线下降≥20%、无需再次青光眼手术、无光感视力丧失。
- 干预为慢凝固连续波TSCPC,功率1250 mW,持续时间4秒。
临床怎么用
- 对于人工晶状体眼且药物控制不佳、无既往青光眼手术史的青光眼患者,可考虑慢凝固TSCPC作为初始手术选择。
- 基线眼压>21 mmHg的患者可能从慢凝固TSCPC中获得更高的成功率。
局限性
- 回顾性病例系列设计,单中心,样本量74例,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Reporting treatment outcomes of slow coagulation transscleral cyclophotocoagulation (TSCPC) as an initial surgical intervention in pseudophakic patients with glaucoma. DESIGN: Retrospective case series. METHODS: This single academic center study reviewed 74 pseudophakic patients who had a diagnosis of glaucoma and no previous glaucoma surgeries (mean age 82.6 ± 12.5 years; mean follow-up 18.7 ± 9.1 months). The intervention used was slow coagulation continuous wave TSCPC (1250-mW power and 4-second duration). The primary outcome measure was surgical success defined as an intraocular pressure (IOP) of 6-21 mm Hg with a ≥20% reduction from baseline, no reoperation for glaucoma, and no loss of light-perception vision. Secondary outcome measures included glaucoma medication use, visual acuity (VA), and complications. RESULTS: IOP decreased from 27.5 ± 9.8 mm Hg preoperatively to 16.1 ± 6.3 mm Hg postoperatively (P < .001). The preoperative number of glaucoma medications was 4.1 ± 0.9 and 3.1 ± 1.3 post-TSCPC (P < .001). The cumulative probabilities of success at 1 and 2 years were 60.6 % and 58.5%, respectively. When patients were divided into 2 groups based on their baseline IOP being >21 mm Hg (high group) or ≤21 mm Hg (low group), success rates at 2 years were 64.9% and 45.5%, respectively (P = .144). The mean logarithm of the minimum angle of resolution VA changed from 0.70 ± 0.64 to 1.04 ± 0.87 at the last follow-up visit (P = .01). No serious complications were observed and most of the complications were mild and transient. CONCLUSIONS: Slow coagulation TSCPC has good efficiency, especially in patients with baseline IOP >21 mm Hg, and safety profile as an initial surgical intervention in pseudophakic patients with glaucoma.
引用
- Khodeiry MM, Sheheitli H, Sayed MS, et al. Treatment Outcomes of Slow Coagulation Transscleral Cyclophotocoagulation In Pseudophakic Patients with Medically Uncontrolled Glaucoma. Am J Ophthalmol. 2021. PMID: 33852906. doi:10.1016/j.ajo.2021.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。